艾码生物科技

Aima Biotech is a pioneering biotechnology company specializing in the development of exosome-based RNA therapeutics through its proprietary SynExo platform. The platform uniquely utilizes the liver as a bio-factory to produce and package therapeutic siRNA into exosomes, which are then distributed via the bloodstream to target organs, including the brain. This approach effectively bypasses the blood-brain barrier, a major hurdle in treating neurodegenerative diseases. The company's lead program, ER-2001, targets BACE1 for the treatment of Alzheimer's disease. Aima Biotech is also expanding its pipeline into oncology and metabolic disorders to leverage its modular delivery technology.